What was the average price paid per share in the repurchase?

LifeVantage repurchased 336,000 shares for approximately $2.0 million, yielding an average price of roughly $5.95 per share during fiscal 2026.

Why did shares outstanding increase despite the buyback?

The company's issued and outstanding shares increased from 12,429 thousand to 12,518 thousand (net +89 thousand) despite the 336,000-share repurchase. This indicates that equity compensation programs or other issuances more than offset the repurchases during the period.

When was the $60 million buyback program authorized?

The Board of Directors approved the $60 million share repurchase program in January 2025, providing the current authorization under which fiscal 2026 repurchases were executed.

How much authorization remains available?

As of June 30, 2026, $58.5 million remained under the program, representing 97.5% of the original $60 million authorization. The company has deployed only $2.0 million to date under the program.

How does this buyback fit with the company's financial position?

LifeVantage's repurchase activity is modest relative to its operational challenges: revenue fell 20% and net income dropped 48% in fiscal 2026. The company is debt-free with $14.9 million in cash, but the conservative use of buyback authorization reflects caution amid business headwinds.

LFVN 8-K Filed 2026-08-27 Execution disclosure

LifeVantage repurchased 336K shares for $2M in fiscal 2026

Company had $58.5M remaining under $60M authorization approved in January 2025

Shares repurchased336K

Avg price paid$5.95

Remaining$58M

MechanismNot specified

What the filing says

LifeVantage Corporation (Nasdaq: LFVN) repurchased approximately 336,000 common shares for an aggregate price of approximately $2.0 million during fiscal year 2026 (ended June 30, 2026), according to its financial results disclosure filed August 27, 2026.

The repurchases were executed under a $60 million share repurchase program approved by the Company's Board of Directors in January 2025. As of June 30, 2026, $58.5 million remained available under this authorization, reflecting the $2.0 million deployed in fiscal 2026 plus prior repurchases.

The execution mechanism was not explicitly specified in the filing. The company's balance sheet shows common shares outstanding decreased from 12,429 thousand at June 30, 2025 to 12,518 thousand at June 30, 2026—a net increase despite the repurchases, indicating additional shares may have been issued through equity compensation or other programs during the period.

During fiscal 2026, the Company repurchased approximately 336,000 of its common shares for an aggregate price of approximately $2.0 million. As of June 30th, there was $58.5 million remaining under the $60 million share repurchase program approved by the Company's Board of Directors in January. — Lifevantage Corp 8-K filing · View on SEC EDGAR →

What this means

LifeVantage deployed modest capital toward share repurchase in a year marked by significant operational headwinds—revenue declined 20.1% to $182.6 million and net income fell 48% to $5.1 million for fiscal 2026. The company maintains substantial authorization capacity ($58.5 million of $60 million) but has used only 3% of the program, suggesting conservative capital deployment during a period of revenue and profit contraction. The company carries no debt and generated $10.2 million in operating cash flow, providing financial flexibility. Further execution rates will likely depend on business stabilization and cash flow trends going forward.

Frequently asked questions

What was the average price paid per share in the repurchase?: LifeVantage repurchased 336,000 shares for approximately $2.0 million, yielding an average price of roughly $5.95 per share during fiscal 2026.
Why did shares outstanding increase despite the buyback?: The company's issued and outstanding shares increased from 12,429 thousand to 12,518 thousand (net +89 thousand) despite the 336,000-share repurchase. This indicates that equity compensation programs or other issuances more than offset the repurchases during the period.
When was the $60 million buyback program authorized?: The Board of Directors approved the $60 million share repurchase program in January 2025, providing the current authorization under which fiscal 2026 repurchases were executed.
How much authorization remains available?: As of June 30, 2026, $58.5 million remained under the program, representing 97.5% of the original $60 million authorization. The company has deployed only $2.0 million to date under the program.
How does this buyback fit with the company's financial position?: LifeVantage's repurchase activity is modest relative to its operational challenges: revenue fell 20% and net income dropped 48% in fiscal 2026. The company is debt-free with $14.9 million in cash, but the conservative use of buyback authorization reflects caution amid business headwinds.

execution small-cap health-wellness fiscal-2026 modest-deployment

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.